EC to doubles health/consumer protection budget:
This article was originally published in Clinica
Executive Summary
If member states give their approval, the European Commission will increase its health and consumer protection budget for 2007-2013 to E1.8bn ($2.3bn), up by 187% on the current 2003-2008 programme. The huge hike will make possible the achievement of a number of key aims, including: supporting co-operation between member state consumer protection authorities to keep dangerous products off the EU's internal market; helping to finance centres of excellence on key health systems; strengthening Europe's surveillance and early warning systems against infectious diseases; and supporting information campaigns to help address some of the main health problems faced by the EU. The Commission also plans to increase the research budget by 166%. Approval of the budgets is due by June.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.